Canaccord lowered the firm’s price target on iRhythm (IRTC) to $180 from $198 and keeps a Buy rating on the shares. The firm said they delivered a solid Q1 with a beat-and-raise. While the guidance range only reflects the Q1 beat, the firm maintaiins the company is making steady progress across its strategic goals. Canaccord believes this is evident by improving operating leverage, signs of increased consistency in its Innovative Channel Partners, and its line of sight for MCT.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm: Strong Q1 Beat, Expanding Zio Adoption and Next-Gen Algorithm Catalyst Underpin Outperform Rating and 2026 Upside
- iRhythm reports Q1 adjusted EPS (35c), consensus (64c)
- iRhythm sees FY26 revenue $875M-$885M, consensus $876.16M
- 2 Under-the-Radar Wearable AI Stocks Analysts Are Bullish On
- iRhythm price target lowered to $170 from $200 at Truist